Evidence map›Paper›PMID 28924457›Full record

ArticleOncotarget2017

Charles Herbaux, Elisabeth Bertrand, Guillemette Marot, Christophe Roumier, Nicolas Poret, Valérie Soenen, Olivier Nibourel, Catherine Roche-Lestienne, Natacha Broucqsault, Sylvie Galiègue-Zouitina and 9 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 1 country.

Charles HerbauxInserm U837, Team 3, Cancer Research Institute of Lille, Lille, France.
Elisabeth BertrandInserm U837, Team 3, Cancer Research Institute of Lille, Lille, France.
Guillemette MarotLille Nord de France University, Equipe Biostatistique, UDSL, Lille, France.
Christophe RoumierLaboratory d'Hématologie, Biologie and Pathologie Center, CHRU, Lille, France.
Nicolas PoretInserm U837, Team 3, Cancer Research Institute of Lille, Lille, France.
Valérie SoenenLaboratory d'Hématologie, Biologie and Pathologie Center, CHRU, Lille, France.
Olivier NibourelLaboratory d'Hématologie, Biologie and Pathologie Center, CHRU, Lille, France.
Catherine Roche-LestienneLaboratory d'Hématologie, Biologie and Pathologie Center, CHRU, Lille, France.
Natacha BroucqsaultInserm U837, Team 3, Cancer Research Institute of Lille, Lille, France.
Sylvie Galiègue-ZouitinaInserm U837, Team 3, Cancer Research Institute of Lille, Lille, France.
Eileen M BoyleService des Maladies du Sang, Hôpital Huriez, CHRU, Lille, France.
Guillemette FouquetService des Maladies du Sang, Hôpital Huriez, CHRU, Lille, France.
Aline RennevilleLaboratory d'Hématologie, Biologie and Pathologie Center, CHRU, Lille, France.
Sabine TricotDépartement d'Hématologie-Immunologie-Cytogénétique, CH, Valenciennes, France.
Franck MorschhauserService des Maladies du Sang, Hôpital Huriez, CHRU, Lille, France.
Claude PreudhommeLaboratory d'Hématologie, Biologie and Pathologie Center, CHRU, Lille, France.
Bruno QuesnelInserm U837, Team 3, Cancer Research Institute of Lille, Lille, France.
Stephanie PoulainDépartement d'Hématologie-Immunologie-Cytogénétique, CH, Valenciennes, France.
Xavier LeleuService d'Hématolgie et Thérapie cellulaire, Hématologie, CHU, Poitiers, France.
Institut de Biologie de Lille · FRHôpital Claude Huriez · FRInstitut pour la Recherche sur le Cancer de Lille · FRInserm · FRCentre Hospitalier de Valenciennes · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Approximately 30% of the patients who fulfil the criteria of Waldenström's macroglobulinemia (WM) are diagnosed while asymptomatic (indolent), and will not require immediate therapy. Conversely, patients with a disease-related event will be considered for therapy. The physiopathology of these 2 groups remains unclear, and the mechanisms of progression from indolent to symptomatic WM have yet to be fully understood. Seventeen patients diagnosed with WM were included in this study, 8 asymptomatic WM (A-WM) and 9 symptomatic WM (S-WM). A differential analysis was performed on a first series of 11 patients and identified 48 genes whose expression separated samples from A- to S-WM. This gene signature was then confirmed on a second independent validation set of 6 WM. Within this expression profile,

Indexed as

BACH2indolentphysiopathologyprogressionWaldenström macroglobulinemia

Identifiers

PMID28924457
PMCPMC5593656
OpenAlexW2411931369

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.